Natera (NTRA) Q3 2025 Earnings Call Transcript
View original at nasdaq.comNatera (NTRA) Q3 2025 Earnings Call Transcript Image source: The Motley Fool. Date Thursday, November 6, 2025 at 4:30 p.m…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
EXPAND trial validated Fetal Focus with >1,700 high-risk pregnancies in diverse multi-ethnic prospective collection with confirmed fetal outcomes
80% confidence2026 preliminary framework targets Signatera rolling 4-quarter average of ~18,000 units per quarter sequential growth
80% confidenceSG&A flat to down from Q2 to Q3 2025 with no near-term large SG&A expansion planned
80% confidenceSignatera-positive patients in INVIGOR 011 achieved 41% overall survival improvement with immunotherapy
80% confidenceSignatera-negative patients achieved 97% overall survival at 24 months with no treatment in INVIGOR 011
80% confidenceMedian bladder cancer diagnosis age is 73 years
80% confidenceFIND CRC study expected enrollment over 18-month cumulative timeframe with ~$50M incremental investment in 2026
80% confidence2026 OpEx growth expected to be approximately 10% focused on R&D and definitive clinical trials
80% confidenceNatera has sequenced >250,000 early-stage tumors for proprietary marker discovery
80% confidenceNICHE study showed 5/6 pathological responders cleared ctDNA pre-surgery and 19/20 non-responders remained ctDNA+ pre-surgery
80% confidenceEarly cancer detection technology detects signals below 0.01% variant allele frequency
80% confidenceGenerated level 1A evidence for Signatera directing treatment post-radical cystectomy
80% confidenceCommercial reimbursement process expected to be steady linear over approximately 2 years
80% confidenceSubstantially raising free cash flow guide to ~$100M for full year
80% confidenceProceed CRC study achieved 22.5% sensitivity and 91.5% specificity for advanced adenoma detection
80% confidenceLong-term gross margin target is 70%+
80% confidenceSignatera has low single-digit penetration including recurrence monitoring market
80% confidenceNatera is one of largest US NGS-based carrier screening providers
80% confidence7 MolDx submissions targeted before year-end worth estimated $250M-$300M gross profit run rate
80% confidenceRaising revenue guidance by $160M at midpoint to $2.18B-$2.26B, full reset of prior range
80% confidenceSignatera uses patented multiplex PCR + NGS with >100,000 reads per target for extreme depth sequencing
80% confidence2026 preliminary framework expects Signatera ASP growth of modest +$50
80% confidenceVEGA study event-based readout likely in 2027 with all patients randomized
80% confidenceINTERCEPT study showed adjuvant therapy achieved MRD clearance in ~25% of post-surgery positive patients with spontaneous clearance rare at 2%-4%
80% confidenceNCCN guideline update for bladder cancer expected mid-late 2026
80% confidence